NewAmsterdam PharmaNAMS
About: NewAmsterdam Pharma Co NV is a late-stage biopharmaceutical company with a mission to improve patient care in populations with metabolic diseases where currently approved therapies have not been adequate or well tolerated. Its product, obicetrapib, is a next-generation, oral, low-dose CETP inhibitor that is developed to potentially overcome the limitations of current LDL-C lowering treatments.
Employees: 62
Fund manager confidence
Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)
1,718% more call options, than puts
Call options by funds: $1.09M | Put options by funds: $60K
159% more repeat investments, than reductions
Existing positions increased: 44 | Existing positions reduced: 17
83% more first-time investments, than exits
New positions opened: 22 | Existing positions closed: 12
11% more funds holding
Funds holding: 90 [Q2] → 100 (+10) [Q3]
5.59% more ownership
Funds ownership: 80.05% [Q2] → 85.64% (+5.59%) [Q3]
0% more funds holding in top 10
Funds holding in top 10: 5 [Q2] → 5 (+0) [Q3]
8% less capital invested
Capital invested by funds: $1.38B [Q2] → $1.28B (-$104M) [Q3]
Research analyst outlook
2 Wall Street Analysts provided 1 year price targets over the past 3 months
2 analyst ratings
Scotiabank George Farmer 20% 1-year accuracy 4 / 20 met price target | 81%upside $47 | Sector Outperform Maintained | 11 Dec 2024 |
Needham Serge Belanger 37% 1-year accuracy 46 / 126 met price target | 39%upside $36 | Buy Reiterated | 5 Dec 2024 |
Financial journalist opinion
Based on 9 articles about NAMS published over the past 30 days